Objective: To observe the clinical therapeutic effects of Wulingsan Jiawei (五苓散加味 Supplemented Powder of Five Drugs with Poria, SPFDP) plus abdominal reinfusion of concentrated ascites after ultrafiltration (ARCA...Objective: To observe the clinical therapeutic effects of Wulingsan Jiawei (五苓散加味 Supplemented Powder of Five Drugs with Poria, SPFDP) plus abdominal reinfusion of concentrated ascites after ultrafiltration (ARCAU) for intractable ascites due to cirrhosis (IAC). Methods: 124 cases of IAC were randomly divided into two groups, a treatment group of 62 cases treated by oral administration of SPFDP plus ARCAU and a control group of 62 cases treated simply by ARCAU. Aldosterone (ALD) level in plasma, levels of total bilirubin (TBIL) and albumin (ALB) in serum, and activity of alanine aminotransferase (ALT) were determined in the two groups before and after treatment. Results: After treatment ALT activity and TBIL level in the treatment group were significantly lower than those in the control group, and ALB content in the treatment group was significantly higher than that in the control group. ALD level of the treatment group significantly decreased after treatment as compared with that before treatment,while that of the control group did not decreased significantly after treatment. The treatment group was significantly superior in keeping down ascites to the control group. Conclusion: SPFDP plus ARCAU treatment of IAC can markedly raise the clinical therapeutic effect, reduce recurrence of ascites, and improve the liver function, which can produce a significant decrease in ALD level in plasma and a marked increase in ALB content.展开更多
文摘Objective: To observe the clinical therapeutic effects of Wulingsan Jiawei (五苓散加味 Supplemented Powder of Five Drugs with Poria, SPFDP) plus abdominal reinfusion of concentrated ascites after ultrafiltration (ARCAU) for intractable ascites due to cirrhosis (IAC). Methods: 124 cases of IAC were randomly divided into two groups, a treatment group of 62 cases treated by oral administration of SPFDP plus ARCAU and a control group of 62 cases treated simply by ARCAU. Aldosterone (ALD) level in plasma, levels of total bilirubin (TBIL) and albumin (ALB) in serum, and activity of alanine aminotransferase (ALT) were determined in the two groups before and after treatment. Results: After treatment ALT activity and TBIL level in the treatment group were significantly lower than those in the control group, and ALB content in the treatment group was significantly higher than that in the control group. ALD level of the treatment group significantly decreased after treatment as compared with that before treatment,while that of the control group did not decreased significantly after treatment. The treatment group was significantly superior in keeping down ascites to the control group. Conclusion: SPFDP plus ARCAU treatment of IAC can markedly raise the clinical therapeutic effect, reduce recurrence of ascites, and improve the liver function, which can produce a significant decrease in ALD level in plasma and a marked increase in ALB content.
